- Home
- NG vs FTRE Comparison
NG vs FTRE Comparison
Compare NG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | FTRE |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NG | FTRE |
|---|---|---|
| Price | $10.49 | $16.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $10.17 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 01-22-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.21 |
| Revenue Next Year | N/A | $0.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $2.26 | $3.97 |
| 52 Week High | $11.29 | $18.82 |
Technical Indicators
Market Signals| Indicator | NG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 53.35 |
| Support Level | $9.34 | $15.37 |
| Resistance Level | $11.29 | $17.81 |
| Average True Range (ATR) | 0.59 | 1.15 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 58.65 | 46.67 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.